ADVANCED ONCOTHERAPY PLC
Advanced Oncotherapy plc was a public limited company registered in England and Wales under company number 05564418, incorporated on 15 September 2005. It traded under two earlier names, Coppersilver Public Limited Company and, from 12 June 2006, CareCapital Group plc, before adopting its current name on 5 September 2012. Its registered office was at 110 Cannon Street, London, EC4N 6EU. Companies House records the company’s status as dissolved, with dissolution taking effect on 5 September 2026.
Advanced Oncotherapy plc developed LIGHT (Linac Image Guided Hadron Technology), a linear proton-beam accelerator system designed to deliver proton therapy for cancer treatment. The underlying technology originated at ADAM S.A., a medical spin-off of CERN based near Geneva, Switzerland, which Advanced Oncotherapy plc acquired in full in September 2013. The company’s first commercial LIGHT system was assembled at a site in Daresbury, Cheshire, where University Hospitals Birmingham NHS Foundation Trust was expected to commission a treatment room, according to contemporaneous company announcements.
Advanced Oncotherapy plc’s ordinary shares were admitted to trading on AIM, a market operated by the London Stock Exchange, under the ticker AVO. Trading in the shares was suspended on 30 June 2023 pending clarification of the company’s financial position, and admission to trading on AIM was cancelled on 9 May 2024, following a regulatory news announcement of that title.
The company entered administration on 30 May 2024, with Ian James Corfield and David Paul Hudson of FRP Advisory appointed as joint administrators. The administrators engaged Hilco to run a sale process; having received no offer for the business as a going concern, they proceeded to market the company’s individual assets. The administration concluded on 5 June 2026, and the company was subsequently dissolved.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
Shareholders of Advanced Oncotherapy plc
Advanced Oncotherapy plc’s most recent Companies House filing on beneficial ownership is a statement, notified 26 June 2017, that the company “knows or has reasonable cause to believe that there is no registrable person or registrable relevant legal entity in relation to the company” – meaning no individual or corporate holder was registered as controlling 25% or more of the company’s shares or voting rights. No person with significant control has been filed since, including throughout the company’s subsequent AIM listing, suspension, administration and dissolution.
Historically, the largest single allotment of shares on record followed the company’s September 2013 acquisition of ADAM S.A.: under the terms disclosed in the company’s own regulatory news announcement of the transaction, 171,072,801 new ordinary shares and 51,112,650 new warrants were issued to the vendor, BRAHMA AG, representing approximately 29.9% of the company’s enlarged share capital at that time. This was a point-in-time allocation from 2013; Advanced Oncotherapy plc carried out numerous further share placings and fundraisings in the following decade, which would have diluted this holding, and no subsequent filing confirms BRAHMA AG’s later shareholding level.
As an AIM-quoted company, Advanced Oncotherapy plc was subject to the London Stock Exchange’s AIM Rules requirement to disclose shareholdings of 3% or more by regulatory news announcement, and a number of “Holding(s) in Company” notices were issued over the years. Trading in the shares was suspended on 30 June 2023 and admission to AIM was cancelled on 9 May 2024, and no complete, dated shareholder register consolidating these notices at a single point in time is available from an official source.
Data availability
Shareholder information for Advanced Oncotherapy plc is best described as historical and partial: the only current Companies House position is the 2017 statement of no registrable significant control, and while individual historical regulatory news disclosures exist, no verified, dated full shareholder register is publicly available following the company’s suspension, delisting and dissolution.
Sources
- Companies House – persons with significant control, ADVANCED ONCOTHERAPY PLC (05564418); retrieved 11 September 2026
- Regulatory news announcement, “Acquisition”, Advanced Oncotherapy plc, 25 September 2013, via Investegate; retrieved 11 September 2026
- Regulatory news announcement, “Cancellation – Advanced Oncotherapy Plc”, 9 May 2024, via Investegate; retrieved 11 September 2026
Officers
35
Directors and officers of Advanced Oncotherapy plc
Companies House records ten officers of Advanced Oncotherapy plc without a recorded resignation date, all holding the role of Director: Michael Stephen Bradfield (appointed 24 April 2013), Hans Henrik Von Celsing (26 January 2017), Lori Jo Cross (29 September 2020), Chunlin Han (28 August 2018), Professor Stephen Myers (26 January 2017), Dr Piers Nicholas Plowman (9 February 2017), Nicolas Serandour (1 September 2014), Dr Michael Jeffrey Sinclair (16 June 2006), Enrico Vanni (1 October 2013) and Renhua Zhang (28 August 2018). A further 17 officers are recorded as resigned, including four company secretaries and 13 directors; the most recent resignation on file is company secretary Henry Edmund Alexander Clarke, who resigned on 14 August 2024, shortly after the company entered administration.
Nationality is officially disclosed for the current directors and varies across the board, including British, Swedish, American, Chinese, Irish/British and French nationals, together with a Swiss national; country of residence is recorded as a separate field and includes England, other parts of the United Kingdom, the United States, China, Portugal, Israel and Monaco. As the company was dissolved on 5 September 2026, these appointments should be read as the last position on file at Companies House rather than as a current, operating board.
Recent officer changes
Company secretary Henry Edmund Alexander Clarke resigned on 14 August 2024, around eleven weeks after the company entered administration on 30 May 2024, according to Companies House filings.
Data availability
Officer information for Advanced Oncotherapy plc is full for the period up to the company’s dissolution: Companies House discloses role, appointment date, nationality and country of residence for each director. Nationality is officially disclosed and has not been inferred from any officer’s name, address or country of residence.
Sources
- Companies House – officers, ADVANCED ONCOTHERAPY PLC (05564418); retrieved 11 September 2026
Registry feed — rows exactly as filed with Companies House, including entries the profile above does not cover.
Group Structure
Group structure of Advanced Oncotherapy plc
Companies House records no registered parent for Advanced Oncotherapy plc: its persons-with-significant-control filing, last updated in 2017, states that no registrable person or entity controls the company. The company’s one verified direct subsidiary is ADAM S.A., a company based near Geneva, Switzerland, and originally a medical spin-off of CERN, which Advanced Oncotherapy plc acquired in full – 100% of the issued share capital – on 25 September 2013, according to the company’s own regulatory news announcement of the transaction.
Internal linkage data associated with this profile also names two further entities that could not be verified as part of Advanced Oncotherapy plc’s group. The London Proton Therapy Centre Limited (company number 09811045), a UK private company, has itself filed a persons-with-significant-control statement declaring no registrable controlling entity, which does not corroborate a parent/subsidiary relationship; it is presented here as a possible, unverified relationship only. CareCapital Gesundheitsimmobilien Verwaltungs GmbH, a healthcare real-estate management company based in Cologne, Germany, was also associated with this profile in internal data, but independent research found it to be an unrelated business with no evident connection to Advanced Oncotherapy plc; this appears to be a data artefact arising from the target company’s former name, CareCapital Group plc (2006-2012), and the entity is not included in the table below.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| ADAM S.A. | Switzerland | Not disclosed in available sources | Direct subsidiary | 100% (acquired 25 Sep 2013) | Historical – parent company dissolved 5 Sep 2026 | 25 September 2013 |
Recent structural changes
Advanced Oncotherapy plc entered administration on 30 May 2024; the administrators subsequently marketed the company’s assets individually after no going-concern buyer was found, and the company was dissolved on 5 September 2026, per Companies House.
Data availability
Corporate-linkage information for Advanced Oncotherapy plc is parent only in the sense that a single verified subsidiary (ADAM S.A.) is confirmed by an official transaction announcement, while other entities referenced in internal profile data could not be corroborated from an authoritative source and are excluded or flagged as unverified above.
Sources
- Companies House – persons with significant control, ADVANCED ONCOTHERAPY PLC (05564418); retrieved 11 September 2026
- Companies House – persons with significant control, THE LONDON PROTON THERAPY CENTRE LIMITED (09811045); retrieved 11 September 2026
- Regulatory news announcement, “Acquisition”, Advanced Oncotherapy plc, 25 September 2013, via Investegate; retrieved 11 September 2026
ADVANCED ONCOTHERAPY PLC
United Kingdom
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does ADVANCED ONCOTHERAPY PLC do?
Advanced Oncotherapy plc was a UK developer of LIGHT (Linac Image Guided Hadron Technology), a proton-beam therapy system for cancer treatment, built on technology from CERN spin-off ADAM S.A., which it acquired in full in September 2013.
Who owns ADVANCED ONCOTHERAPY PLC?
Companies House records no registered person with significant control since a 2017 statement that no individual or entity held 25% or more of the company; in 2013 the vendor of ADAM S.A., BRAHMA AG, received shares representing about 29.9% of the enlarged share capital, though this holding would have been diluted by later fundraisings.
Who is ADVANCED ONCOTHERAPY PLC's UBO (Ultimate Beneficial Owner)?
No ultimate beneficial owner is confirmed: Companies House's persons-with-significant-control filing states that no registrable individual or entity controlled 25% or more of Advanced Oncotherapy plc as of the last statement filed in 2017.
What is ADVANCED ONCOTHERAPY PLC's company registration number?
ADVANCED ONCOTHERAPY PLC's registration number is 05564418, filed with Companies House in United Kingdom. Its current status on the register is active.
Is ADVANCED ONCOTHERAPY PLC still an active company?
ADVANCED ONCOTHERAPY PLC's status on Companies House is listed as active.
When was ADVANCED ONCOTHERAPY PLC incorporated?
ADVANCED ONCOTHERAPY PLC was incorporated on 15 September 2005, according to Companies House.
What is ADVANCED ONCOTHERAPY PLC's registered address?
The registered address on file for ADVANCED ONCOTHERAPY PLC is London, United Kingdom.
What legal structure is ADVANCED ONCOTHERAPY PLC registered as?
ADVANCED ONCOTHERAPY PLC is registered as a Public Limited Company in United Kingdom.
What is ADVANCED ONCOTHERAPY PLC's revenue?
No recent revenue figure is publicly available: the company's last filed accounts covered the year ended 31 December 2021, and it was suspended from AIM in June 2023 before entering administration in May 2024.
Is ADVANCED ONCOTHERAPY PLC listed on a stock exchange?
Advanced Oncotherapy plc's ordinary shares traded on AIM (London Stock Exchange) under the ticker AVO; trading was suspended on 30 June 2023 and admission to AIM was cancelled on 9 May 2024.
Who are the officers/directors of ADVANCED ONCOTHERAPY PLC?
Companies House lists ten directors with no recorded resignation date, including long-serving director Michael Jeffrey Sinclair (appointed 2006) and Michael Stephen Bradfield (appointed 2013), alongside seventeen resigned officers including company secretary Henry Edmund Alexander Clarke, who resigned in August 2024 shortly after the company entered administration.
Does ADVANCED ONCOTHERAPY PLC have a parent company or subsidiaries?
Advanced Oncotherapy plc had no registered parent company. Its one verified subsidiary was ADAM S.A. of Switzerland, acquired in full in September 2013; other entities linked to the company in internal data, including a German real-estate company, could not be verified as part of its corporate group.
Can Zavia monitor changes to ADVANCED ONCOTHERAPY PLC's ownership over time?
This profile reflects a point-in-time snapshot from Companies House. Zavia's monitoring API can track changes to ADVANCED ONCOTHERAPY PLC's registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access ADVANCED ONCOTHERAPY PLC's data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including United Kingdom, so records like ADVANCED ONCOTHERAPY PLC's registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Companies House and was last synced on 8 September 2026.